HC Wainwright & Co. Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $397
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has maintained a Buy rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and increased the price target from $390 to $397.
December 11, 2023 | 12:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vertex Pharmaceuticals' Buy rating is maintained by HC Wainwright & Co., with a raised price target from $390 to $397, indicating a positive outlook on the stock.
The increase in price target by HC Wainwright & Co. suggests a strong confidence in Vertex Pharmaceuticals' future performance. This endorsement by a reputable analyst could lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100